Search Results - "Meggendorfer, M."

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases by Stengel, A, Kern, W, Haferlach, T, Meggendorfer, M, Fasan, A, Haferlach, C

“…Alterations in TP53 have been described in many cancer types including hematological neoplasms. We aimed at comparing TP53 mutations (mut) and deletions (del)…”
Get full text

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis by Jawhar, M, Schwaab, J, Schnittger, S, Meggendorfer, M, Pfirrmann, M, Sotlar, K, Horny, H-P, Metzgeroth, G, Kluger, S, Naumann, N, Haferlach, C, Haferlach, T, Valent, P, Hofmann, W-K, Fabarius, A, Cross, N C P, Reiter, A

“…Most patients with KIT D816V + advanced systemic mastocytosis (SM) are characterized by somatic mutations in additional genes. We sought to clarify the…”
Get full text

SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations by Meggendorfer, M, Bacher, U, Alpermann, T, Haferlach, C, Kern, W, Gambacorti-Passerini, C, Haferlach, T, Schnittger, S

“…Chronic myeloid malignancies are categorized to the three main categories myeloproliferative neoplasms (MPNs), myelodysplastic syndromes (MDSs) and MDS/MPN…”
Get full text

Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML by Stengel, A, Kern, W, Meggendorfer, M, Nadarajah, N, Perglerovà, K, Haferlach, T, Haferlach, C

“…RUNX1 -mutated acute myeloid leukemia (AML) show a distinct pattern of genetic abnormalities and an adverse prognosis. We analyzed the impact of multiple RUNX1…”
Get full text

SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis by Meggendorfer, M, Kern, W, Haferlach, C, Haferlach, T, Schnittger, S

Get full text

Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia by Meggendorfer, Manja, Haferlach, Torsten, Alpermann, Tamara, Jeromin, Sabine, Haferlach, Claudia, Kern, Wolfgang, Schnittger, Susanne

Get full text

The new provisional WHO entity ‘RUNX1 mutated AML’ shows specific genetics but no prognostic influence of dysplasia by Haferlach, T, Stengel, A, Eckstein, S, Perglerová, K, Alpermann, T, Kern, W, Haferlach, C, Meggendorfer, M

Get full text

MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations by Stengel, A, Kern, W, Meggendorfer, M, Haferlach, T, Haferlach, C

Get full text

Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD) by Sun, Q-Y, Ding, L-W, Tan, K-T, Chien, W, Mayakonda, A, Lin, D-C, Loh, X-Y, Xiao, J-F, Meggendorfer, M, Alpermann, T, Garg, M, Lim, S-L, Madan, V, Hattori, N, Nagata, Y, Miyano, S, Yeoh, A E J, Hou, H-A, Jiang, Y-Y, Takao, S, Liu, L-Z, Tan, S-Z, Lill, M, Hayashi, M, Kinoshita, A, Kantarjian, H M, Kornblau, S M, Ogawa, S, Haferlach, T, Yang, H, Koeffler, H P

“…Partial tandem duplication of MLL ( MLL-PTD ) characterizes acute myeloid leukemia (AML) patients often with a poor prognosis. To understand the order of…”
Get full text

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms by Rinke, J, Müller, J P, Blaess, M F, Chase, A, Meggendorfer, M, Schäfer, V, Winkelmann, N, Haferlach, C, Cross, N C P, Hochhaus, A, Ernst, T

“…Mutations in the epigenetic regulator gene EZH2 are frequently observed in patients with myelodysplastic/myeloproliferative neoplasms (MDS/MPN; 10–13%) and are…”
Get full text

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis by Martinelli, G, Mancini, M, De Benedittis, C, Rondoni, M, Papayannidis, C, Manfrini, M, Meggendorfer, M, Calogero, R, Guadagnuolo, V, Fontana, M C, Bavaro, L, Padella, A, Zago, E, Pagano, L, Zanotti, R, Scaffidi, L, Specchia, G, Albano, F, Merante, S, Elena, C, Savini, P, Gangemi, D, Tosi, P, Ciceri, F, Poletti, G, Riccioni, L, Morigi, F, Delledonne, M, Haferlach, T, Cavo, M, Valent, P, Soverini, S

“…The molecular basis of advanced systemic mastocytosis (SM) is not fully understood and despite novel therapies the prognosis remains dismal. Exome sequencing…”
Get full text

The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers by Meggendorfer, M, Haferlach, C, Zenger, M, Macijewski, K, Kern, W, Haferlach, T

Get full text

Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations by Vetro, C, Haferlach, C, Haferlach, T, Zenger, M, Nadarajah, N, Kern, W, Meggendorfer, M

Get full text

Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN by Jeromin, S, Kohlmann, A, Meggendorfer, M, Schindela, S, Perglerová, K, Nadarajah, N, Kern, W, Haferlach, C, Haferlach, T, Schnittger, S

Get full text

Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia by Meggendorfer, Manja, de Albuquerque, Andreia, Nadarajah, Niroshan, Alpermann, Tamara, Kern, Wolfgang, Steuer, Kimberly, Perglerová, Karolína, Haferlach, Claudia, Schnittger, Susanne, Haferlach, Torsten

Get full text

P411: SF3B1 MUTATIONS IN AML ARE STRONGLY ASSOCIATED WITH MECOM REARRANGEMENTS AND MAY BE INDICATIVE OF AN MDS PRE‐PHASE by Huber, S., Hutter, S., Meggendorfer, M., Hoermann, G., Walter, W., Baer, C., Kern, W., Haferlach, T., Haferlach, C.

Get full text

P735: THE ROLE OF SF3B1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES by Huber, S., Hutter, S., Meggendorfer, M., Hoermann, G., Walter, W., Baer, C., Kern, W., Haferlach, T., Haferlach, C.

Get full text

Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards by Haferlach, T, Weber, S, Konietschke, R, Nadarajah, N, Stengel, A, Kern, W, Haferlach, C, Meggendorfer, M

Get full text

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia by Weber, S, Alpermann, T, Dicker, F, Jeromin, S, Nadarajah, N, Eder, C, Fasan, A, Kohlmann, A, Meggendorfer, M, Haferlach, C, Kern, W, Haferlach, T, Schnittger, S

“…High brain and acute leukemia, cytoplasmic ( BAALC ) expression defines an important risk factor in cytogenetically normal acute myeloid leukemia (CN-AML). The…”
Get full text

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q by Heuser, M, Meggendorfer, M, Cruz, M M A, Fabisch, J, Klesse, S, Köhler, L, Göhring, G, Ganster, C, Shirneshan, K, Gutermuth, A, Cerny-Reiterer, S, Krönke, J, Panagiota, V, Haferlach, C, Koenecke, C, Platzbecker, U, Thiede, C, Schroeder, T, Kobbe, G, Ehrlich, S, Stamer, K, Döhner, K, Valent, P, Schlegelberger, B, Kroeger, N, Ganser, A, Haase, D, Haferlach, T, Thol, F

Get full text